-
Clinical Trials & Development2 months agoRoivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, 'significantly exceeded expectations' in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage...
-
Clinical Trials & Development2 months agoEight Trends Reshaping Patient-Centric Drug Development
Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and...
-
Clinical Trials & Development2 months agoPrediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.
-
Clinical Trials & Development2 months agoNovartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in...
-
Clinical Trials & Development2 months agoNovartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular...
-
Clinical Trials & Development2 months agoSTAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies
An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.
-
Clinical Trials & Development2 months ago
Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after...
-
Clinical Trials & Development2 months agoSTAT+: Roivant lung disease drug hits mid-stage study goals
These positive results could open up a new way to treat serious lung disease.
-
Clinical Trials & Development2 months ago
Spyre’s 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
-
Clinical Trials & Development2 months agoSTAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
A Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
